hVIVO’s (HVO) “Buy” Rating Reaffirmed at Shore Capital Group

Shore Capital Group reissued their buy rating on shares of hVIVO (LON:HVO) in a report issued on Wednesday, Marketbeat reports.

Separately, Stifel Nicolaus restated a “hold” rating and set a GBX 10 price objective on shares of hVIVO in a report on Wednesday, April 15th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 15.

hVIVO Stock Down 3.8%

Shares of LON HVO opened at GBX 8.80 on Wednesday. The company has a debt-to-equity ratio of 38.75, a current ratio of 1.63 and a quick ratio of 1.16. The company has a market cap of £60.58 million, a P/E ratio of 11.43 and a beta of 1.67. hVIVO has a 1 year low of GBX 4.31 and a 1 year high of GBX 19.50. The firm has a 50-day simple moving average of GBX 7.96 and a two-hundred day simple moving average of GBX 6.87.

hVIVO (LON:HVO) last released its earnings results on Wednesday, April 15th. The company reported GBX (0.87) EPS for the quarter. The business had revenue of GBX 4,677 million for the quarter. hVIVO had a negative net margin of 12.48% and a negative return on equity of 14.65%. Research analysts anticipate that hVIVO will post 1.5492958 earnings per share for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.